BioMarin Pharma (BMRN) Misses Q3 EPS by 2c
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $63.37 --0%
Revenue Growth %: +31.4%
Financial Fact:
NET INCOME (LOSS): -42.8M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Revenue Growth %: +31.4%
Financial Fact:
NET INCOME (LOSS): -42.8M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q3 EPS of ($0.04), $0.02 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $505.3 million versus the consensus estimate of $516.56 million.
GUIDANCE:
BioMarin Pharma sees 2022 revenue of $2.06-2.16 billion, versus the consensus of $2.12 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- KB Home (KBH) Tops Q3 EPS by 16c
- Getty Realty (GTY) Reiterated at Market Outperform by Citizens on Investment Volumes
- AnaptysBio, Inc. (ANAB) Tops Q2 EPS by 524c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
